Read Books Online and Download eBooks, EPub, PDF, Mobi, Kindle, Text Full Free.
Bortezomib In The Treatment Of Multiple Myeloma
Download Bortezomib In The Treatment Of Multiple Myeloma full books in PDF, epub, and Kindle. Read online Bortezomib In The Treatment Of Multiple Myeloma ebook anywhere anytime directly on your device. Fast Download speed and no annoying ads. We cannot guarantee that every ebooks is available!
Book Synopsis Bortezomib in the Treatment of Multiple Myeloma by : Irene M. Ghobrial
Download or read book Bortezomib in the Treatment of Multiple Myeloma written by Irene M. Ghobrial and published by Springer Science & Business Media. This book was released on 2010-10-20 with total page 183 pages. Available in PDF, EPUB and Kindle. Book excerpt: Multiple Myeloma (MM) is the second most common type of blood cancer, resulting from an overproduction of cancerous infection-fighting white blood cells, known as plasma cells. Plasma cells are a crucial part of the immune system responsible for the production of antibodies. Bortezomib is a promising anticancer drug targeting the proteasome. This proteasome inhibitor induces cell stress and apoptosis in the cancer cells. While multiple mechanisms are likely to be involved, proteasome inhibition may prevent the degradation of pro-apoptotic factors, permitting activation of programmed cell death in neoplastic cells dependent upon the suppression of proapoptotic pathways. This monograph on bortezomib is a valuable source of information for researchers and clinicians from the fields of oncology and pharmacology, working either in academia or the pharmaceutical industry.
Book Synopsis Bortezomib in the Treatment of Multiple Myeloma by : Irene M. Ghobrial
Download or read book Bortezomib in the Treatment of Multiple Myeloma written by Irene M. Ghobrial and published by Springer. This book was released on 2010-11-11 with total page 180 pages. Available in PDF, EPUB and Kindle. Book excerpt: Multiple Myeloma (MM) is the second most common type of blood cancer, resulting from an overproduction of cancerous infection-fighting white blood cells, known as plasma cells. Plasma cells are a crucial part of the immune system responsible for the production of antibodies. Bortezomib is a promising anticancer drug targeting the proteasome. This proteasome inhibitor induces cell stress and apoptosis in the cancer cells. While multiple mechanisms are likely to be involved, proteasome inhibition may prevent the degradation of pro-apoptotic factors, permitting activation of programmed cell death in neoplastic cells dependent upon the suppression of proapoptotic pathways. This monograph on bortezomib is a valuable source of information for researchers and clinicians from the fields of oncology and pharmacology, working either in academia or the pharmaceutical industry.
Book Synopsis Proteasome Inhibitors in Cancer Therapy by : Julian Adams
Download or read book Proteasome Inhibitors in Cancer Therapy written by Julian Adams and published by Springer Science & Business Media. This book was released on 2004-05-25 with total page 319 pages. Available in PDF, EPUB and Kindle. Book excerpt: A panel of leading academic and pharmaceutical investigators takes stock of the remarkable work that has been accomplished to date with proteasome inhibitors in cancer, and examines emerging therapeutic possibilities. The topics range from a discussion of the chemistry and cell biology of the proteasome and the rationale for proteasome inhibitors in cancer to a review of current clinical trials underway. The discussion of rationales for testing proteasome inhibitors in cancer models covers the role of the proteasome in NF-kB activation, the combining of conventional chemotherapy and radiation with proteasome inhibition, notably PS-341, new proteasome methods of inhibiting viral maturation, and the role of protesome inhibition in the treatment of AIDS. The authors also document the development of bortezomib (VelcadeTM) in Phase I clinical trials and in a multicentered Phase II clinical trials in patients with relapsed and refractory myeloma.
Book Synopsis Hepatotoxicity by : Hyman J. Zimmerman
Download or read book Hepatotoxicity written by Hyman J. Zimmerman and published by Lippincott Williams & Wilkins. This book was released on 1999 with total page 848 pages. Available in PDF, EPUB and Kindle. Book excerpt: Written by the foremost authority in the field, this volume is a comprehensive review of the multifaceted phenomenon of hepatotoxicity. Dr. Zimmerman examines the interface between chemicals and the liver; the latest research in experimental hepatotoxicology; the hepatotoxic risks of household, industrial, and environmental chemicals; and the adverse effects of drugs on the liver. This thoroughly revised, updated Second Edition features a greatly expanded section on the wide variety of drugs that can cause liver injury. For quick reference, an appendix lists these medications and their associated hepatic injuries. Also included are in-depth discussions of drug metabolism and factors affecting susceptibility to liver injury.
Book Synopsis Drug-Induced Liver Disease by : Neil Kaplowitz
Download or read book Drug-Induced Liver Disease written by Neil Kaplowitz and published by CRC Press. This book was released on 2002-10-16 with total page 790 pages. Available in PDF, EPUB and Kindle. Book excerpt: Featuring more than 4100 references, Drug-Induced Liver Disease will be an invaluable reference for gastroenterologists, hepatologists, family physicians, internists, pathologists, pharmacists, pharmacologists, and clinical toxicologists, and graduate and medical school students in these disciplines.
Book Synopsis Update on Multiple Myeloma by : Khalid Ahmed Al-Anazi
Download or read book Update on Multiple Myeloma written by Khalid Ahmed Al-Anazi and published by . This book was released on 2019-02 with total page 236 pages. Available in PDF, EPUB and Kindle. Book excerpt: This book is a comprehensive overview of the recent developments in the clinical and research fields of multiple myeloma. It is divided into three main sections that cover a wide range of topics, including: epidemiology and pathogenesis of the disease, genetic targets and pathways, resistance to novel therapies, angiogenesis and anti-angiogenesis, hematopoietic stem cell transplantation, role of radiology and radiotherapy in myeloma, infectious complications, and management of multiple myeloma in resource-poor countries.
Book Synopsis Multiple Myeloma by : Morie A. Gertz
Download or read book Multiple Myeloma written by Morie A. Gertz and published by Springer Science & Business Media. This book was released on 2013-10-01 with total page 311 pages. Available in PDF, EPUB and Kindle. Book excerpt: This is a comprehensive, state-of-the-art guide to the diagnosis, treatment, and biology of multiple myeloma and related plasma disorders. Edited and written by a multidisciplinary group of recognized authorities from the Mayo Clinic, it presents clear guidelines on diagnosis and therapy and covers all aspects of multiple myeloma, from molecular classification and diagnosis, to risk stratification and therapy. Closely related plasma cell disorders such as solitary plasmacytoma, Waldenstrom macroglobulinemia, and light chain amyloidosis are discussed in detail as well. The book addresses often overlooked topics, including the role of radiation therapy, vertebral augmentation, and supportive care. Our understanding of this group of disorders is developing at an unprecedented rate, and Multiple Myeloma meets the need among oncologists and hematologists for a clear, timely, and authoritative resource on their biology, diagnosis, and treatment.
Book Synopsis Multiple Myeloma by : Thomas Moehler
Download or read book Multiple Myeloma written by Thomas Moehler and published by Springer Science & Business Media. This book was released on 2011-04-21 with total page 349 pages. Available in PDF, EPUB and Kindle. Book excerpt: Multiple myeloma is currently still an incurable disease, but during the past decade knowledge of its molecular pathogenesis has increased rapidly. This has led to remarkable progress in both diagnosis and therapy, including in particular the approval of novel and first-in-class drugs such as thalidomide, bortezomib, and lenalidomide. This book, written by internationally acknowledged experts, covers a wide range of topics relating to multiple myeloma, including history, epidemiology, pathophysiology, clinical features, staging, and prognostic systems. The principal focus, however, is on therapy, with detailed information on the various promising treatment options which give hope that this cancer will be transformed into a chronic disease or even become curable. Individualized therapy and the variety of supportive treatment options, as described in this volume, will help in achieving this goal, as well as in reducing adverse events and improving quality of life.
Book Synopsis Heart Failure: A Companion to Braunwald's Heart Disease E-Book by : G. Michael Felker
Download or read book Heart Failure: A Companion to Braunwald's Heart Disease E-Book written by G. Michael Felker and published by Elsevier Health Sciences. This book was released on 2019-02-06 with total page 937 pages. Available in PDF, EPUB and Kindle. Book excerpt: Up-to-date, authoritative and comprehensive, Heart Failure, 4th Edition, provides the clinically relevant information you need to effectively manage and treat patients with this complex cardiovascular problem. This fully revised companion to Braunwald's Heart Disease helps you make the most of new drug therapies such as angiotensin receptor neprilysin inhibitors (ARNIs), recently improved implantable devices, and innovative patient management strategies. Led by internationally recognized heart failure experts Dr. G. Michael Felker and Dr. Douglas Mann, this outstanding reference gives health care providers the knowledge to improve clinical outcomes in heart failure patients. - Focuses on a clinical approach to treating heart failure, resulting from a broad variety of cardiovascular problems. - Covers the most recent guidelines and protocols, including significant new updates to ACC, AHA, and HFSA guidelines. - Covers key topics such as biomarkers and precision medicine in heart failure and new data on angiotensin receptor neprilysin inhibitors (ARNIs). - Contains four new chapters: Natriuretic Peptides in Heart Failure; Amyloidosis as a Cause of Heart Failure; HIV and Heart Failure; and Neuromodulation in Heart Failure. - Covers the pathophysiological basis for the development and progression of heart failure. - Serves as a definitive resource to prepare for the ABIM's Heart Failure board exam. - 2016 British Medical Association Award: First Prize, Cardiology (3rd Edition).
Book Synopsis Elsevier's 2022 Intravenous Medications - E-Book by : Shelly Rainforth Collins
Download or read book Elsevier's 2022 Intravenous Medications - E-Book written by Shelly Rainforth Collins and published by Elsevier Health Sciences. This book was released on 2021-04-16 with total page 1408 pages. Available in PDF, EPUB and Kindle. Book excerpt: Find the essential information you need to safely administer more than 400 intravenous drugs! For more than 45 years, Gahart’s Intravenous Medications: A Handbook for Nurses and Health Professionals has been a trusted resource for comprehensive drug coverage, unparalleled accuracy, and an intuitive quick-access format. In addition to updated drug interactions, precautions, alerts, and patient teaching instructions for all existing IV drugs, the 2022 edition includes approximately 10 new monographs of the most recent IV drugs to be approved by the FDA. Administering intravenous drugs is a critical task — inaccurate or out-of-date information is not an option. Known as the #1 IV drug handbook on the market, and with its history of impeccable accuracy, Gahart’s annual publication gives you the extra confidence and guidance you need to safely and effectively treat patients. Monographs on more than 400 IV drugs offer an impressive breadth of coverage that goes well beyond any comparable drug reference. Updated annual publication prevents you from referencing outdated information. Additional drug monographs are provided on the companion Evolve website. 45-year history of impeccable accuracy reinforces the importance of safe IV drug administration. Perfect depth of information equips you with everything that is needed for safe administration of IV drugs — nothing more, nothing less. Proven, clinically optimized format keeps all dosage information for each drug on either a single page or a two-page spread to prevent hand contamination by having to turn a page. Highlighted Black Box Warnings and relevant content make locating critical information fast and easy. Special circumstances in blue-screened text call attention to important circumstances that may not warrant Black Box Warnings. Life-stage dosage variances are highlighted for geriatric, pediatric, infant, and neonatal patients. Dilution and dosage charts within monographs provide quick access to essential clinical information. Convenient, alphabetical format organizes all drug monographs by generic name, allowing you to find any drug in seconds. NEW! Drug monographs for newly approved drugs by the FDA provide you with the most current drug information. Updates on drug interactions, precautions, alerts, and more have been made throughout the guide to reflect all changes to existing medications.
Book Synopsis Pomalidomide, Bortezomib, and Dexamethasone for Multiple Myeloma Previously Treated with Lenalidomide (OPTIMISMM): Outcomes by Prior Treatment at First Relapse by : Meletios A. Dimopoulos
Download or read book Pomalidomide, Bortezomib, and Dexamethasone for Multiple Myeloma Previously Treated with Lenalidomide (OPTIMISMM): Outcomes by Prior Treatment at First Relapse written by Meletios A. Dimopoulos and published by . This book was released on 2021 with total page pages. Available in PDF, EPUB and Kindle. Book excerpt: Abstract: In the phase 3 OPTIMISMM trial, pomalidomide, bortezomib, and dexamethasone (PVd) demonstrated superior efficacy vs bortezomib and dexamethasone (Vd) in patients with relapsed or refractory multiple myeloma previously treated with lenalidomide, including those refractory to lenalidomide. This analysis evaluated outcomes in patients at first relapse (N = 226) by lenalidomide-refractory status, prior bortezomib exposure, and prior stem cell transplant (SCT). Second-line PVd significantly improved PFS vs Vd in lenalidomide-refractory (17.8 vs 9.5 months; P = 0.0276) and lenalidomide-nonrefractory patients (22.0 vs 12.0 months; P = 0.0491), patients with prior bortezomib (17.8 vs 12.0 months; P = 0.0068), and patients with (22.0 vs 13.8 months; P = 0.0241) or without (16.5 vs 9.5 months; P = 0.0454) prior SCT. In patients without prior bortezomib, median PFS was 20.7 vs 9.5 months (P = 0.1055). Significant improvement in overall response rate was also observed with PVd vs Vd in lenalidomide-refractory (85.9% vs 50.8%; P
Download or read book OPLL written by Atsushi Okawa and published by Springer Nature. This book was released on 2020-05-14 with total page 278 pages. Available in PDF, EPUB and Kindle. Book excerpt: This publication brings together information on all aspects of OPLL - epidemiology, etiology, diagnosis, and treatment. It contains contributions by Japanese researchers and surgeons, including members of the Ministry of Health and Welfare Investigation Committee, and by American surgeons with expertise in the field. Until now, little has been published on the subject in English. This collection of reports is amply augmented with illustrations.
Book Synopsis Myeloma Bone Disease by : G. David Roodman
Download or read book Myeloma Bone Disease written by G. David Roodman and published by Springer Science & Business Media. This book was released on 2010-04-28 with total page 257 pages. Available in PDF, EPUB and Kindle. Book excerpt: This book presents the forefront in the science and clinical management of myeloma bone disease. Coverage begins with sections on clinical presentation, imaging, and biochemical markers and goes on to discuss radiation, surgical, and medical therapies.
Book Synopsis Combined Treatment of Bortezomib, Continuous Low-dose Cyclophosphamide and Dexamethasone Followed by One Year of Maintenance Treatment for Refractory Or Relapsed Multiple Myeloma Patients by : Esther G. M. de Waal
Download or read book Combined Treatment of Bortezomib, Continuous Low-dose Cyclophosphamide and Dexamethasone Followed by One Year of Maintenance Treatment for Refractory Or Relapsed Multiple Myeloma Patients written by Esther G. M. de Waal and published by . This book was released on 2014 with total page 4 pages. Available in PDF, EPUB and Kindle. Book excerpt:
Book Synopsis Multiple Myeloma - A New Era of Treatment Strategies by : Klaus Podar
Download or read book Multiple Myeloma - A New Era of Treatment Strategies written by Klaus Podar and published by Bentham Science Publishers. This book was released on 2012-01-03 with total page 217 pages. Available in PDF, EPUB and Kindle. Book excerpt: "Multiple Myeloma (MM), the second most common blood cancer in adults, is a clonal plasma cell malignancy within the bone marrow characterized by osteolytic bone lesions, renal disease, and immunodeficiency. It is now well established that MM cell- induced"
Book Synopsis Amitryptilin Strengthens Effects of Bortezomib and Melphalan Treatment in Multiple Myeloma by Inhibiting Acid Sphingomyelinase. U00a0 by : Inge Oudaert
Download or read book Amitryptilin Strengthens Effects of Bortezomib and Melphalan Treatment in Multiple Myeloma by Inhibiting Acid Sphingomyelinase. U00a0 written by Inge Oudaert and published by . This book was released on 2017 with total page pages. Available in PDF, EPUB and Kindle. Book excerpt: ObjectiveMalignant cells can adapt their lipid metabolism to attain higher rates of proliferation, and resist chemotherapy-induced apoptosis. The aim of our study was to first identify the changes in lipid metabolism in multiple myeloma (MM) patients, and to further investigate the role of this altered metabolism in vitro. MethodsWe performed a lipidomics analysis to compare plasma from MM patients to healthy controls. Based on these results, lipid spike-in assays enabled us to evaluate effects on MM cell proliferation. Sphingomyelinase (SMase) content of MM cells was measured, before and after treatment with standard-of-care drugs, using an AmplexRed assay. We inhibited both neutral and acid SMase in MM cells to evaluate effects on drug efficacy. To eliminate possible off-target effects, our findings were confirmed by silencing SMPD1 expression. ResultsLipidomics analysis revealed that several ceramide species were significantly more present in MM patient plasma, while sphingomyelin seemed to be decreased. When adding ceramide in vitro to MM cells, we observed higher viability and proliferation. The increased ceramide/sphingomyelin ratio in plasma lead us to believe that the sphingomyelinase enzyme, which converts sphingomyelin into ceramide, was upregulated in MM cells. This was confirmed in BM samples, comparing CD138+ MM cells to the CD138 negative fraction. In the MM cell lines JJN3, OPM2, LP1 and U266, we observed an increased expression of acid and total SMase when treating these cells with melphalan or bortezomib for 24hInterestingly, amitryptiline, an inhibitor of acid SMase, often prescribed in MM patients for neuropathic pain, increased the efficacy of both drugs in vitro, and also induced apoptosis in primary MM cells as a single agent. ConclusionSMase is increased in primary MM cells and cell lines upon treatment with melphalan and bortezomib, while inhibiting this expression using amitryptilin leads to a higher efficacy of drug therapy.
Book Synopsis The Proteasome — Ubiquitin Protein Degradation Pathway by : Peter Zwickl
Download or read book The Proteasome — Ubiquitin Protein Degradation Pathway written by Peter Zwickl and published by Springer Science & Business Media. This book was released on 2012-12-06 with total page 222 pages. Available in PDF, EPUB and Kindle. Book excerpt: This volume gives an overview of pro tea some-mediated protein degradation and the regulatory role of the ubiquitin system in cellular proteolysis. The first chapter describes the molecular evolution of the proteasome and its associated activators, i. e. , the 20S core, the base and the lid of the 19S cap, and the 11 S regulator. The ensuing chapter gives an overview of the structure and assembly of the 20S proteasome and the regulation of the archaeal proteasome by PAN. The third contribution summarizes our knowledge on the eukaryotic 26S proteasome and its regulation by the 19S regu lator, followed by a chapter devoted to the llS regulator, which elucidates the structural basis for the 11 S-mediated activation of the 20S proteasome. The fifth chapter reviews in detail the role of the proteasome in the immune response. The subsequent chapter of the natural substrates of the gives a comprehensive description proteasome and their recognition by the enzymes of the ubiqui tination machinery. The penultimate chapter rounds up the in formation on intracellular distribution of proteasomes in yeast and mammalian cells, while the last contribution highlights proteasome inhibitors, tools which proved to be very valuable for dissecting the cellular roles of the proteasome and which might turn out to be of pharmacological importance.
